{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:38:26Z","timestamp":1787740706223,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejca.2025.116110","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T03:08:29Z","timestamp":1763608109000},"page":"116110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age"],"prefix":"10.1016","volume":"232","author":[{"given":"Neal D.","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matko","family":"Kalac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan","family":"Croitoru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igle J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio M.","family":"Carcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116110_bib1","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/cancers14174149","article-title":"The effect of age on prostate cancer survival","volume":"14","author":"Clark","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116110_bib2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cncr.32630","article-title":"Impact of age at diagnosis of de novo metastatic prostate cancer on survival","volume":"126","author":"Bernard","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.116110_bib3","first-page":"496","article-title":"Comorbidity burden and health-related quality of life in men with advanced prostate cancer","volume":"31","author":"Benzo","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2025.116110_bib4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/ageing\/afn022","article-title":"Aerobic reserve and physical functional performance in older adults","volume":"37","author":"Arnett","year":"2008","journal-title":"Age Ageing"},{"key":"10.1016\/j.ejca.2025.116110_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116110_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0070","article-title":"Assessment and management of cardiovascular risk factors among US veterans with prostate cancer","volume":"4","author":"Sun","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2025.116110_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.116110_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2021.10.015","article-title":"Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region","volume":"159","author":"De Giorgi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116110_bib9","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.euo.2023.11.012","article-title":"Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and \u226575 Years: ARCHES Post Hoc Analysis","volume":"7","author":"Gomez-Veiga","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejca.2025.116110_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41416-023-02492-8","article-title":"Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN","volume":"130","author":"Shen","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.116110_bib11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdv542","article-title":"Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL","volume":"27","author":"Graff","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116110_bib12","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2025.116110_bib13","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and quality of life in biochemically recurrent prostate cancer","volume":"2","author":"Freedland","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2025.116110_bib14","unstructured":"Astellas Pharma Inc. Patient Information: XTANDI\u00ae (enzalutamide). 2023. https:\/\/\u3008www.astellas.us\/docs\/us\/12A005-ENZ-Patient%20Package%20Insert-WPI.pdf?v=1\u3009. [accessed: May 8, 2024]."},{"key":"10.1016\/j.ejca.2025.116110_bib15","unstructured":"Astellas Pharma Europe B.V. Summary of Product Characteristics: XTANDI\u00ae (enzalutamide) 40 mg soft capsules. 2021. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf\u3009. [accessed: 29 May, 2022]."},{"key":"10.1016\/j.ejca.2025.116110_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the advanced prostate cancer consensus conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116110_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046588","article-title":"A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design","volume":"11","author":"Freedland","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2025.116110_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/COC.0b013e318243708f","article-title":"Impact of a prostate multidisciplinary clinic program on patient treatment decisions and on adherence to NCCN guidelines: the William Beaumont Hospital experience","volume":"36","author":"Korman","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116110_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102630","article-title":"Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer","volume":"122","author":"Efstathiou","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.116110_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bju.14780","article-title":"Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment","volume":"124","author":"Reichard","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.ejca.2025.116110_bib21","first-page":"1823","article-title":"A multidisciplinary group for prostate cancer management: a single institution experience","volume":"15","author":"Colasante","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejca.2025.116110_bib22","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/S2666-7568(22)00169-6","article-title":"Integrated geriatric assessment and treatment effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial","volume":"3","author":"Soo","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"43","key":"10.1016\/j.ejca.2025.116110_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390396","article-title":"Management of prostate Cancer in Older Adults","author":"Graham","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2025.116110_bib24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/archinternmed.2009.71","article-title":"A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial","volume":"169","author":"Gillespie","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.116110_bib25","article-title":"Medication review in hospitalised patients to reduce morbidity and mortality","author":"Christensen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2025.116110_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/UPJ.0000000000000473","article-title":"A proposal for the comprehensive care of men on androgen deprivation therapy: recommendations from the multidisciplinary prostate cancer 360 working group","volume":"11","author":"Crawford","year":"2024","journal-title":"Urol Pract"},{"key":"10.1016\/j.ejca.2025.116110_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s13063-021-05687-7","article-title":"Protocol for GET FIT Prostate: a randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer","volume":"22","author":"Winters-Stone","year":"2021","journal-title":"Trials"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:41:26Z","timestamp":1768844486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"alternative-id":["S0959804925009967"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116110","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116110"}}